KR-20260067752-A - COMPOSITION FOR PREVENTING OR TREATING HYPERTENSION COMPRISING ALGINIC ACID EXTRACT FROM ECKLONIA CAVA

Abstract

The present invention relates to a composition for the prevention or treatment of hypertension containing an alginic acid extract derived from Ecklonia cava as an active ingredient. Since the alginic acid extract derived from Ecklonia cava has excellent antioxidant activity, cell protective activity, and nitric oxide (NO) production ability, it can be utilized as a pharmaceutical composition, a health functional food composition, and an adjunct treatment for hypertension for the prevention, treatment, or improvement of hypertension.

Inventors

• 김현수
• 최유리
• 구혜민
• 육태경

Assignees

• 경상국립대학교산학협력단

Dates

Publication Date

20260513

Application Date

20241106

Claims (8)

1. A pharmaceutical composition for the prevention or treatment of hypertension containing an alginic acid extract derived from Ecklonia cava as an active ingredient.
2. In Article 1, The above alginate extract is, A pharmaceutical composition characterized by increasing the production of nitric oxide (NO), an endothelial relaxant released from vascular endothelial cells.
3. In Article 1, The above alginate extract is, A pharmaceutical composition characterized by having antioxidant activity and cell protective effects.
4. A health functional food composition for preventing or improving hypertension, containing an alginic acid extract derived from Ecklonia cava as an active ingredient.
5. An adjuvant for treating hypertension containing an alginic acid extract derived from Ecklonia cava as an active ingredient.
6. In Article 5, The above therapeutic adjuvant is, An adjuvant for the treatment of hypertension characterized by being administered simultaneously or sequentially with a hypertension treatment drug.
7. A method for preventing or treating hypertension, comprising the step of administering an alginic acid extract derived from Ecklonia cava to mammals other than humans.
8. An antioxidant composition containing an alginic acid extract derived from Ecklonia cava as an active ingredient.

Description

Composition for preventing or treating hypertension containing alginic acid extract derived from Ecklonia cava as an active ingredient The present invention relates to a natural antihypertensive agent, and more specifically, to a composition for preventing or treating hypertension containing an alginic acid extract derived from Ecklonia cava as an active ingredient. Seaweeds have a high carbohydrate content, and brown algae, in particular, contain approximately 30–67% carbohydrates on a dry matter basis. Most of the polysaccharides in brown algae consist of alginic acid, laminaran, and fucoidan. Recently, as studies have been published indicating that seaweed polysaccharides possess various physiological activities, they are receiving significant attention for various functional purposes. Among them, alginic acid is known as a hetero-type polysaccharide composed of β-D-mannuronic acid (M) and α-L-guluronic acid (G) linked by α-1,4 or β-1,4 bonds, serving as a major component of cell membranes or intercellular substances. Recently, there have been reports that alginic acid naturally forms biopolymers (gels) by binding with various metals (Co, Cu, Cd, Zn, etc.), and that the synthesized material possesses ion exchange capabilities. Furthermore, these biopolymers are known to have the ability to adsorb heavy metals from the environment. Alginic acid has the advantage of being able to be synthesized into biodegradable polymers with diverse properties through processing methods or manipulation of additives. By utilizing the extraction, purification, and polymer synthesis technologies of various biopolymers reported to date, it is possible to develop polymers with diverse properties and apply them to a wide range of high-value-added industrial materials, such as adsorbents for environmental pollutants, and additives for food, pharmaceuticals, and cosmetics. However, approximately 87% of the domestic imports of alginate in 2021 are imported from China, and there is currently no data secured regarding the clear characteristics, safety, or stability of the imported alginate. Meanwhile, blood pressure is regulated by changes in cardiac output and peripheral resistance, and peripheral resistance is determined by changes in blood vessel diameter. A representative factor that can influence vascular tone is vascular endothelial cells, and substances released from these cells include endothelial relaxants and endothelial-dependent contractiles. Endothelial-dependent relaxants are known as nitric oxide (NO), and this substance is produced by NO-producing enzymes. Subsequently, NO is known to act to relax vascular smooth muscle by increasing intracellular cyclic GMP levels. Most conventional drugs used to treat hypertension frequently cause various side effects, such as increasing blood viscosity, inducing diabetes, worsening heart failure, and impairing kidney function. Furthermore, since hypertension cannot be fundamentally cured, patients face the problem of having to take these medications for life; consequently, there is currently a surge in research aimed at discovering new pharmacologically active substances using native plants. Figure 1 is the result of analyzing the ABTS radical scavenging activity of an alginate extract derived from Ecklonia cava according to the present invention. Figure 2 shows the results confirming the cell-protective effect of alginic acid extract derived from Ecklonia cava. Figure 3 shows the results of confirming the production of nitric oxide (NO) in cells by the alginate extract derived from Ecklonia cava. The present invention will be described in detail below. The inventors obtained an alginic acid extract from Ecklonia cava and confirmed its excellent antioxidant activity, cell protective effect through macrophages, and nitric oxide (NO) production ability, thereby completing the present invention. The present invention provides a pharmaceutical composition for the prevention or treatment of hypertension containing an alginic acid extract derived from Ecklonia cava as an active ingredient. In this specification, " Ecklonia cava " is a perennial seaweed of the family Laminariales, order Laminariales, distributed in temperate coastal areas such as the Korean Peninsula and Japan, and is mainly found in the coastal areas of Jeju Island and Ulleung-gun, Gyeongsangbuk-do, and is widely used in the fields of food additives, livestock feed, and fertilizer. In this specification, the term "extract" refers to a substance obtained by extracting components of a natural product, regardless of the extraction method, extraction solvent, extracted components, or form of the extract, and may include all substances that can be obtained by processing or treating the substance obtained by extracting components of a natural product through other methods after extraction. The above extract may be extracted according to methods commonly used in the relevant technical field, such as hot water extraction, ultr